Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,190 shares of the medical equipment provider’s stock after purchasing an additional 289 shares during the period. Maryland State Retirement & Pension System’s holdings in Intuitive Surgical were worth $9,173,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. OFI Invest Asset Management purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at about $25,000. Baystate Wealth Management LLC raised its holdings in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the period. MCF Advisors LLC raised its holdings in shares of Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 40 shares during the period. Headinvest LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at about $28,000. Finally, Stone House Investment Management LLC raised its holdings in shares of Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 50 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Shares of ISRG traded up $1.69 during midday trading on Monday, hitting $383.05. 878,161 shares of the stock traded hands, compared to its average volume of 1,616,046. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The firm has a market capitalization of $135.87 billion, a PE ratio of 69.14, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. The business’s 50 day moving average price is $385.29 and its two-hundred day moving average price is $351.11.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of several analyst reports. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Citigroup lifted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Truist Financial lifted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Wells Fargo & Company lifted their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Finally, Piper Sandler lifted their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Activity

In other news, President David J. Rosa sold 80,710 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the transaction, the president now owns 163,399 shares of the company’s stock, valued at $63,607,962.72. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, President David J. Rosa sold 80,710 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the transaction, the president now directly owns 163,399 shares in the company, valued at approximately $63,607,962.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 228,637 shares of company stock valued at $88,483,248. 0.80% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.